Bone Marrow Involvement by Lymphoproliferative Disorders After Solid-Organ Transplant

dc.contributor.authorOzkan, Eylem Akar
dc.contributor.authorOzdemir, B. Handan
dc.contributor.authorAkcay, Eda Yilmaz
dc.contributor.authorTerzi, Aysen
dc.contributor.authorKarakus, Sema
dc.contributor.authorHaberal, Mehmet
dc.contributor.orcID0000-0002-7528-3557en_US
dc.contributor.orcID0000-0002-1225-1320en_US
dc.contributor.orcID0000-0001-6831-9585en_US
dc.contributor.orcID0000-0002-3462-7632en_US
dc.contributor.orcID0000-0001-7615-4581en_US
dc.contributor.pubmedID25894151en_US
dc.contributor.researcherIDX-8540-2019en_US
dc.contributor.researcherIDF-7546-2013en_US
dc.contributor.researcherIDAAK-1960-2021en_US
dc.contributor.researcherIDAAJ-8097-2021en_US
dc.contributor.researcherIDW-9092-2019en_US
dc.date.accessioned2024-02-08T07:51:44Z
dc.date.available2024-02-08T07:51:44Z
dc.date.issued2015
dc.description.abstractObjectives: Posttransplant lymphoproliferative disorders are classified as monomorphic, polymorphic, early lesions, or Hodgkin lymphoma. Bone marrow staging examination is recommended in posttransplant lymphoproliferative disorder patients. However, information about bone marrow involvement in these disorders is scarce. We evaluated 19 transplant patients with posttransplant lymphoproliferative disorder to investigate incidence of bone marrow involvement, associated morphologic changes, and prognosis. Materials and Methods: We retrospectively assessed bone marrow findings of 19 transplant patients with posttransplant lymphoproliferative disorder who underwent bone marrow staging at Baskent University from 1985 to 2013. Clinical and pathologic data were reviewed from the medical records. Follow-up information was obtained from medical records or communication with patients or families. Data collected including age, sex, Epstein-Barr virus status, immunosuppressive therapy, elapsed time from transplant to diagnosis of posttransplant lymphoproliferative disorder, B symptoms, number of extranodal sites, involvement of different organs, Ann Arbor clinical staging, hematologic parameters, and serum lactate dehydrogenase levels. Results: There were 5 of 19 patients (26.3%) who had bone marrow involvement with posttransplant lymphoproliferative disorder, including 2 patients diagnosed with posttransplant lymphoproliferative disorder by lymph node biopsy and 1 patient each diagnosed by native liver biopsy, nasopharyngeal biopsy, or allograft liver biopsy. In 4 patients, there was monomorphic posttransplant lymphoproliferative disorder subtype and 1 patient had early lesion posttransplant lymphoproliferative disorder subtype. In 10 of 19 patients (52.6%), Epstein-Barr virus was detected with in situ hybridization, including 3 patients with bone marrow involvement who were diagnosed with Burkitt lymphoma (n = 1), diffuse large B-cell lymphoma (n = 1), or early lesion (n = 1). Conclusions: Patients with posttransplant lymphoproliferative disorder have high incidence of bone marrow involvement and high mortality rates. Therefore, bone marrow examination may be important in the diagnosis and staging evaluation of posttransplant lymphoproliferative disorder.en_US
dc.identifier.endpage187en_US
dc.identifier.issn1304-0855en_US
dc.identifier.issueSupplement 1en_US
dc.identifier.scopus2-s2.0-84939781301en_US
dc.identifier.startpage183en_US
dc.identifier.urihttp://hdl.handle.net/11727/11467
dc.identifier.volume13en_US
dc.identifier.wos000355058400035en_US
dc.language.isoengen_US
dc.relation.isversionof10.6002/ect.mesot2014.O154en_US
dc.relation.journalEXPERIMENTAL AND CLINICAL TRANSPLANTATIONen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergien_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectEpstein-Barr virusen_US
dc.subjectPosttransplant lymphoproliferative disorderen_US
dc.subjectStagingen_US
dc.titleBone Marrow Involvement by Lymphoproliferative Disorders After Solid-Organ Transplanten_US
dc.typearticleen_US

Files

License bundle

Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description: